Lyell Immunopharma (LYEL) Amortizatization of Intangibles (2020 - 2026)
Lyell Immunopharma recorded quarterly Amortizatization of Intangibles of $886000.0 in Q1 2026, down 16.42% quarter-over-quarter from $1.1 million in Q4 2025, and down 48.64% year-over-year from $1.7 million in Q1 2025.
Lyell Immunopharma's Amortizatization of Intangibles history runs 7 years deep, the most recent figure standing at $886000.0 for Q1 2026.
- In Q1 2026, Amortizatization of Intangibles fell 48.64% year-over-year to $886000.0; the TTM figure through Mar 2026 stood at $4.1 million (down 65.78% YoY), while the FY2025 annual figure was $5.0 million, down 66.22% from the prior year.
- Amortizatization of Intangibles came in at $886000.0 for Q1 2026 at Lyell Immunopharma, down from $1.1 million in the prior quarter.
- In the past five years, Amortizatization of Intangibles ranged from a high of $4.4 million in Q1 2024 to a low of -$475000.0 in Q1 2022.
- A 5-year average of $1.8 million and a median of $1.7 million in 2025 frame the typical range for Amortizatization of Intangibles.
- Across the five-year window, Amortizatization of Intangibles surged 998.27% in 2023 and sank 71.87% in 2025, its largest moves.
- Lyell Immunopharma's Amortizatization of Intangibles stood at $1.2 million in 2022, then jumped by 180.13% to $3.4 million in 2023, then declined by 12.38% to $3.0 million in 2024, then plunged by 64.25% to $1.1 million in 2025, then dropped by 16.42% to $886000.0 in 2026.
- According to Business Quant data, Amortizatization of Intangibles over the past three periods registered $886000.0, $1.1 million, and $1.0 million for Q1 2026, Q4 2025, and Q3 2025 respectively.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Amortizatization of Intangibles (Qtr) |
|---|---|---|---|---|---|
| 1 | Quantum Biopharma | 1,216,509.61 Bn | 1,216,509.61 Bn | - | 13,267.00 |
| 2 | Alterity Therapeutics | 764,224.41 Bn | 764,224.38 Bn | - | - |
| 3 | Legend Biotech | 2,716.00 Bn | 2,715.71 Bn | 242.10 Mn | - |
| 4 | Nanobiotix | 2,248.83 Bn | 2,248.77 Bn | - | - |
| 5 | Akari Therapeutics | 1,951.18 Bn | 1,951.17 Bn | - | - |
| 6 | Vertex Pharmaceuticals | 113.69 Bn | 106.44 Bn | 2.59 Bn | - |
| 7 | Evaxion A | 64.16 Bn | 64.14 Bn | - | - |
| 8 | Regeneron Pharmaceuticals | 63.94 Bn | 55.18 Bn | 3.31 Bn | - |
| 9 | Alnylam Pharmaceuticals | 40.13 Bn | 37.12 Bn | 959.66 Mn | - |
| 10 | Lyell Immunopharma | 379.11 Mn | 379.11 Mn | - | 886,000.00 |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 886,000.00 |
| Mar 31, 2026 | 886,000.00 |
| Dec 31, 2025 | 1.06 Mn |
| Dec 31, 2025 | 1.06 Mn |
| Sep 30, 2025 | 1.01 Mn |
| Sep 30, 2025 | 1.01 Mn |
| Jun 30, 2025 | 1.17 Mn |
| Jun 30, 2025 | 1.17 Mn |
| Mar 31, 2025 | 1.73 Mn |
| Mar 31, 2025 | 1.73 Mn |
| Dec 31, 2024 | 2.97 Mn |
| Dec 31, 2024 | 2.97 Mn |
| Sep 30, 2024 | 3.59 Mn |
| Sep 30, 2024 | 3.59 Mn |
| Jun 30, 2024 | 3.76 Mn |
| Jun 30, 2024 | 3.76 Mn |
| Mar 31, 2024 | 4.37 Mn |
| Mar 31, 2024 | 4.37 Mn |
| Dec 31, 2023 | 3.38 Mn |
| Dec 31, 2023 | 3.38 Mn |
| Sep 30, 2023 | 2.29 Mn |
| Sep 30, 2023 | 2.29 Mn |
| Jun 30, 2023 | 2.08 Mn |
| Jun 30, 2023 | 2.08 Mn |
| Mar 31, 2023 | 1.85 Mn |
| Mar 31, 2023 | 1.85 Mn |
| Dec 31, 2022 | 1.21 Mn |
| Dec 31, 2022 | 1.21 Mn |
| Sep 30, 2022 | 428,000.00 |
| Sep 30, 2022 | 428,000.00 |
| Jun 30, 2022 | -231,000.00 |
| Jun 30, 2022 | -231,000.00 |
| Mar 31, 2022 | -475,000.00 |
| Mar 31, 2022 | -475,000.00 |
| Dec 31, 2021 | -467,000.00 |
| Dec 31, 2021 | -467,000.00 |
| Sep 30, 2021 | -552,000.00 |
| Sep 30, 2021 | -552,000.00 |
| Jun 30, 2021 | -399,000.00 |
| Jun 30, 2021 | -399,000.00 |
| Mar 31, 2021 | -483,000.00 |
| Mar 31, 2021 | -483,000.00 |
| Dec 31, 2020 | -472,000.00 |
| Dec 31, 2020 | -472,000.00 |
| Sep 30, 2020 | -185,000.00 |
| Sep 30, 2020 | -185,000.00 |